000			01465 am a22002533u 4500
042			_adc
100	1	0	_aDe Picker, Livia J. _eauthor _91097
700	1	0	_aLeboyer, Marion _eauthor _91098
700	1	0	_aGeddes, John R. _eauthor _91099
700	1	0	_aMorrens, Manuel _eauthor _91100
700	1	0	_aHarrison, Paul J. _eauthor _91101
700	1	0	_aTaquet, Maxime _eauthor _91102
245	0	0	_aAssociation between serum lithium level and incidence of COVID-19 infection
260			_c2022-07-01.
500			_a/pmc/articles/PMC7612897/
500			_a/pubmed/35318909
520			_aAn antiviral effect of lithium has been proposed, but never investigated for COVID-19. Using electronic health records of 26,554 patients with documented serum lithium levels during the pandemic, we show that the 6-month COVID-19 infection incidence was lower among matched patients with 'therapeutic' (0.50-1.00) vs. 'sub-therapeutic' (0.05-0.50) lithium levels (HR 0.82, 95% CI 0.69-0.97, p=0.017) and among patients with 'therapeutic' lithium levels vs. matched patients using valproate (HR 0.79, 95% CI 0.67-0.92, p=0.0023). Lower rates of infection were observed for both new COVID-19 diagnoses and positive PCR tests, regardless of underlying psychiatric diagnosis and vaccination status.
540			_a
546			_aen
690			_aArticle
655	7		_aText _2local
786	0		_nBr J Psychiatry
856	4	1	_uhttp://dx.doi.org/10.1192/bjp.2022.42 _zConnect to this object online.
999			_c1721 _d1721